Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Collateral damage : the impact on outcomes from cancer surgery of the COVID-19 pandemic

BACKGROUND: Cancer diagnostics and surgery have been disrupted by the response of health care services to the coronavirus disease 2019 (COVID-19) pandemic. Progression of cancers during delay will impact on patients' long-term survival

PATIENTS AND METHODS: We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of 3 and 6 months and periods of disruption of 1 and 2 years. Using health care resource costing, we contextualise attributable lives saved and life-years gained (LYGs) from cancer surgery to equivalent volumes of COVID-19 hospitalisations

RESULTS: Per year, 94 912 resections for major cancers result in 80 406 long-term survivors and 1 717 051 LYGs. Per-patient delay of 3/6 months would cause attributable death of 4755/10 760 of these individuals with loss of 92 214/208 275 life-years, respectively. For cancer surgery, average LYGs per patient are 18.1 under standard conditions and 17.1/15.9 with a delay of 3/6 months (an average loss of 0.97/2.19 LYGs per patient), respectively. Taking into account health care resource units (HCRUs), surgery results on average per patient in 2.25 resource-adjusted life-years gained (RALYGs) under standard conditions and 2.12/1.97 RALYGs following delay of 3/6 months. For 94 912 hospital COVID-19 admissions, there are 482 022 LYGs requiring 1 052 949 HCRUs. Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5.08 LYG and 0.46 RALYGs

CONCLUSIONS: Modest delays in surgery for cancer incur significant impact on survival. Delay of 3/6 months in surgery for incident cancers would mitigate 19%/43% of LYGs, respectively, by hospitalisation of an equivalent volume of admissions for community-acquired COVID-19. This rises to 26%/59%, respectively, when considerin... Full description

Year of Publication: 2020
Contained in: Annals of oncology : official journal of the European Society for Medical Oncology Vol. 31, No. 8 (2020), p. 1065-1074
All journal articles: Search for all articles in this journal
Language: English
Contributors: Sud, A | Author
Jones, M E
Broggio, J
Loveday, C
Torr, B
Garrett, A
Nicol, D L
Jhanji, S
Boyce, S A
Gronthoud, F
Ward, P
Handy, J M
Yousaf, N
Larkin, J
Suh, Y-E
Scott, S
Pharoah, P D P
Swanton, C
Abbosh, C
Williams, M
Lyratzopoulos, G
Houlston, R
Turnbull, C
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
delay
diagnostics
oncology
survival
Additional Keywords: *Betacoronavirus
Adult
Aged
Aged, 80 and over
Coronavirus Infections
Female
Hospitalization
Humans
Male
Middle Aged
Neoplasms
Pandemics
Pneumonia, Viral
Time-to-Treatment
Treatment Outcome
ISSN: 1569-8041
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 12.08.2020
Date Revised 12.08.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32442581
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.annonc.2020.05.009
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 05466nma a2201033 c 4500
001 NLM311121772
003 DE-601
005 20200813213935.0
007 cr uuu---uuuuu
008 200523s2020 000 0 eng d
024 7 |a 10.1016/j.annonc.2020.05.009  |2 doi 
028 5 2 |a pubmed20n1300.xml 
035 |a S0923-7534(20)39825-2 
035 |a (DE-599)NLM32442581 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Sud, A 
245 1 0 |a Collateral damage  |h Elektronische Ressource  |b the impact on outcomes from cancer surgery of the COVID-19 pandemic 
300 |a Online-Ressource 
500 |a Date Completed 12.08.2020 
500 |a Date Revised 12.08.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. 
520 |a BACKGROUND: Cancer diagnostics and surgery have been disrupted by the response of health care services to the coronavirus disease 2019 (COVID-19) pandemic. Progression of cancers during delay will impact on patients' long-term survival 
520 |a PATIENTS AND METHODS: We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of 3 and 6 months and periods of disruption of 1 and 2 years. Using health care resource costing, we contextualise attributable lives saved and life-years gained (LYGs) from cancer surgery to equivalent volumes of COVID-19 hospitalisations 
520 |a RESULTS: Per year, 94 912 resections for major cancers result in 80 406 long-term survivors and 1 717 051 LYGs. Per-patient delay of 3/6 months would cause attributable death of 4755/10 760 of these individuals with loss of 92 214/208 275 life-years, respectively. For cancer surgery, average LYGs per patient are 18.1 under standard conditions and 17.1/15.9 with a delay of 3/6 months (an average loss of 0.97/2.19 LYGs per patient), respectively. Taking into account health care resource units (HCRUs), surgery results on average per patient in 2.25 resource-adjusted life-years gained (RALYGs) under standard conditions and 2.12/1.97 RALYGs following delay of 3/6 months. For 94 912 hospital COVID-19 admissions, there are 482 022 LYGs requiring 1 052 949 HCRUs. Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5.08 LYG and 0.46 RALYGs 
520 |a CONCLUSIONS: Modest delays in surgery for cancer incur significant impact on survival. Delay of 3/6 months in surgery for incident cancers would mitigate 19%/43% of LYGs, respectively, by hospitalisation of an equivalent volume of admissions for community-acquired COVID-19. This rises to 26%/59%, respectively, when considering RALYGs. To avoid a downstream public health crisis of avoidable cancer deaths, cancer diagnostic and surgical pathways must be maintained at normal throughput, with rapid attention to any backlog already accrued 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Observational Study  |2 gnd 
611 2 7 |a Research Support, Non-U.S. Gov't  |2 gnd 
653 2 |a Adult  |6 D000328 
653 2 |a Aged  |6 D000368 
653 2 |a Aged, 80 and over  |6 D000369 
653 2 |a *Betacoronavirus  |6 D000073640 
653 2 |a Coronavirus Infections  |6 D018352  |a diagnosis  |6 Q000175  |a *epidemiology  |6 Q000453  |a therapy  |6 Q000628 
653 2 |a Female  |6 D005260 
653 2 |a Hospitalization  |6 D006760  |a trends  |6 Q000639 
653 2 |a Humans  |6 D006801 
653 2 |a Male  |6 D008297 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Neoplasms  |6 D009369  |a diagnosis  |6 Q000175  |a *epidemiology  |6 Q000453  |a *surgery  |6 Q000601 
653 2 |a Pandemics  |6 D058873  |a *prevention & control  |6 Q000517 
653 2 |a Pneumonia, Viral  |6 D011024  |a diagnosis  |6 Q000175  |a *epidemiology  |6 Q000453  |a therapy  |6 Q000628 
653 2 |a Time-to-Treatment  |6 D061665  |a *trends  |6 Q000639 
653 2 |a Treatment Outcome  |6 D016896 
655 7 |a COVID-19  |2 gnd 
655 7 |a delay  |2 gnd 
655 7 |a diagnostics  |2 gnd 
655 7 |a oncology  |2 gnd 
655 7 |a survival  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Observational Study 
689 0 2 |A f  |a Research Support, Non-U.S. Gov't 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a delay 
689 1 2 |a diagnostics 
689 1 3 |a oncology 
689 1 4 |a survival 
689 1 |5 DE-601 
700 1 |a Jones, M E 
700 1 |a Broggio, J 
700 1 |a Loveday, C 
700 1 |a Torr, B 
700 1 |a Garrett, A 
700 1 |a Nicol, D L 
700 1 |a Jhanji, S 
700 1 |a Boyce, S A 
700 1 |a Gronthoud, F 
700 1 |a Ward, P 
700 1 |a Handy, J M 
700 1 |a Yousaf, N 
700 1 |a Larkin, J 
700 1 |a Suh, Y-E 
700 1 |a Scott, S 
700 1 |a Pharoah, P D P 
700 1 |a Swanton, C 
700 1 |a Abbosh, C 
700 1 |a Williams, M 
700 1 |a Lyratzopoulos, G 
700 1 |a Houlston, R 
700 1 |a Turnbull, C 
773 0 8 |i in  |t Annals of oncology : official journal of the European Society for Medical Oncology  |g Vol. 31, No. 8 (2020), p. 1065-1074  |q 31:8<1065-1074  |w (DE-601)NLM012606391  |x 1569-8041 
856 4 1 |u http://dx.doi.org/10.1016/j.annonc.2020.05.009  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 31  |j 2020  |e 8  |b 21  |c 08  |h 1065-1074